Learn about the groundbreaking cardiovascular care offered at the Mount Sinai Health System. Ranked by U.S. News & World Report as No. 6 in the nation for Cardiology and Heart Surgery, Mount Sinai Heart at The Mount Sinai Hospital is recognized internationally as a leader in advancing all aspects of cardiology care, cardiac surgery, and cardiovascular research. Under the leadership of Valentín Fuster, MD, PhD, our team of award-winning physicians is expanding the field of knowledge in cardiovascular medicine, including treatments for arrhythmias, coronary artery disease, heart failure, valvular disease, and vascular disease.
Learn about the groundbreaking cardiovascular care offered at the Mount Sinai Health System. Ranked by U.S. News & World Report as No. 6 in the nation for Cardiology and Heart Surgery, Mount Sinai Heart at The Mount Sinai Hospital is recognized internationally as a leader in advancing all aspects of cardiology care, cardiac surgery, and cardiovascular research. Under the leadership of Valentín Fuster, MD, PhD, our team of award-winning physicians is expanding the field of knowledge in cardiovascular medicine, including treatments for arrhythmias, coronary artery disease, heart failure, valvular disease, and vascular disease.
Mount Sinai Health System’s globally acclaimed cardiologist Valentín Fuster, MD, PhD, has been named President of Mount Sinai Heart, a newly created position, effective Sunday, January 1, 2023.
Join Valentín Fuster, MD, PhD, MACC and a panel of experts for a discussion on the top late-breaking clinical trials released during the ACC 2023 Conference.
Twenty-six weeks of PCSK9 inhibitor therapy on top of maximally tolerated statins increases markers of plaque stability in patients with stable coronary artery disease, according to the YELLOW III trial, led by Annapoorna S. Kini, MD, ...
Post hoc analysis data demonstrated pegozafermin treatment significantly reduced triglycerides and other atherogenic lipids in patients with SHTG regardless of their background lipid-modifying therapy status.
Mount Sinai researchers help identify previously unknown genetic causes of primary lymphedema, thoracic aortic aneurysm disease, and congenital deafness.
Message From the President: I am honored to update you on a year of high achievement at Mount Sinai Heart, which is driven by a unified mission—better control and prevention of heart disease.
Globally acclaimed cardiologist Valentin Fuster, MD, PhD, has been named President of Mount Sinai Heart, a newly created position. Deepak L. Bhatt, MD, MPH, a top expert in cardiovascular medicine and interventional cardiology, has been named Director.
In a milestone in cardiovascular medicine, a three-drug medication known as a “polypill” was found effective in preventing adverse events such as heart attacks or stroke in people who have previously had a heart attack...
A unique Mount Sinai study focused on a multiethnic, underserved community in Harlem found that young non-Hispanic Black adult participants were twice as likely to have atherosclerosis as young Hispanic adults.
Patients identified by nuclear stress testing as having severe stress-induced myocardial ischemia are likely to benefit from heart bypass surgery or angioplasty, while those with mild or no ischemia are not.
Mount Sinai Heart is launching a multispecialty Women's Heart and Vascular Center, with clinics specifically designed to screen, assess, and educate women about their level of individual risk
Chronic, insufficient sleep can negatively affect immune cells, which may lead to inflammatory disorders and cardiovascular disease, according to a study from the Icahn School of Medicine at Mount Sinai.
The Cardiovascular Research Institute is building on Mount Sinai’s legacy of discovery and innovation with a renewed focus on lifestyle and prevention, systems physiology and bioengineering, and genetic medicine.
The Center for Inherited Cardiovascular Diseases was established in 2022, positioning Mount Sinai Heart at the forefront of cardiovascular genomic medicine.
Bivalirudin is a safer and more effective anticoagulant than heparin for treating patients with the most serious type of heart attacks who undergo PCI, and can lower the risk of death or major bleeding by 31 percent.
To improve outcomes of STEMI patients, Mount Sinai Heart developed a secure mobile app to streamline real-time communication and coordination between multiple teams.
The study is the first to look at COVID-19 vaccination status and outcomes in patients with heart failure and has indicated significant protective effects in this high-risk patient population.
Higher concentrations of lipoprotein(a) have long been associated with atherosclerosis and aortic stenosis, but no drug therapies that lower this concentration are approved. Olpasiran shows promise.
A novel type of therapy, known as ANGPTL3 inhibitor therapy, was effective in lowering triglycerides in certain types of patients with severe hypertriglyceridemia (sHTG) who had a prior episode(s) of acute pancreatitis.
High-dose anticoagulation can reduce deaths by 30 percent and intubations by 25 percent in hospitalized COVID-19 patients who are not critically ill when compared to the standard treatment, which is low-dose anticoagulation.
Fasting may be detrimental to fighting off infection, and could lead to an increased risk of heart disease, according to a new study by the Icahn School of Medicine at Mount Sinai.
The TCT Career Achievement Award has been presented to Valentin Fuster, MD, PhD, today, September 17, 2022, at the 34th Transcatheter Cardiovascular Therapeutics (TCT), the annual scientific symposium of the Cardiovascular Research Foundation (CRF).
The award recognizes Dr. Mehran’s outstanding record of effectively mentoring women cardiologists and underscores the importance of mentoring in the professional development of women.
Implementing school-based programs aimed at teaching healthy cardiovascular health habits as early as preschool can achieve lasting lifestyle changes in children, according to a review published today in the Journal of the American College of Cardiology.
In a milestone in cardiovascular medicine, a three-drug medication known as a “polypill” was found effective in preventing adverse events such as heart attacks or stroke in people who have previously had a heart attack
This year, The Mount Sinai Hospital was ranked among the top 6 in the nation for cardiology and cardiac surgery, according to U.S. News & World Report, and ranked No. 4 in the world by Newsweek.
A unique Mount Sinai study focused on a multiethnic, underserved community in Harlem found that young non-Hispanic Black adult participants were twice as likely to have atherosclerosis as young Hispanic adults.
The Cardio-Oncology Program at The Mount Sinai Hospital, under the directorship of Gagan Sahni, MD, has been awarded Gold Center of Excellence status. This is the highest designation of certification from the International Cardio-Oncology ...
Heart failure patients who are unvaccinated against SARS-CoV-2, the virus that causes COVID-19, are three times more likely to die if infected with the virus compared to fully boosted heart failure patients, according to new research out of Mount Sinai Heart.
Valentín Fuster, MD, PhD, Director of Mount Sinai Heart, Physician-in-Chief of The Mount Sinai Hospital in New York, and Editor-in-Chief of JACC, hosts the annual Cardiology Hour and includes commentary on multiple late-breaking clinical ...
A new, updated risk score can help predict possible contrast-associated acute kidney injury (CA-AKI) among patients undergoing percutaneous coronary intervention (PCI), Mount Sinai researchers report.
As the Endowed Chair of Cardiovascular Research and Outcomes at the Icahn School of Medicine at Mount Sinai, Roxana Mehran, MD, is the lead Commissioner of the Lancet women and cardiovascular disease Commission
Gastroenterology and Mount Sinai Heart are among the specialties recognized at The Mount Sinai Hospital in Newsweek’s “The World’s Best Specialized Hospitals 2021.”
Join David H. Adams, MD, in discussion with Randall B. Griepp, MD, for the “Legend Series” lectureship at the Department of Cardiovascular Surgery at the Icahn School of Medicine at Mount Sinai
Each week, Valentin Fuster, MD, PhD, MACC, renowned editor-in-chief of the Journal of the American College of Cardiology (JACC), records a free podcast highlighting journal findings.
Dr. Dong Zhao questions her distinguished panel of experts and editors as they discuss essential qualities in pursuing clinical research for cardiologists, both in the US and China, as well as identifying good research topics and research practices.
A breakthrough study found that the TriClip™ transcatheter edge-to-edge repair (TEER) system was safe for patients with severe tricuspid regurgitation, reduced the severity of tricuspid regurgitation, and was associated with an improvement in quality of life.
First-generation bioresorbable vascular scaffolds (BVS) may be just as effective as drug-eluting metallic stents, which are currently the standard treatment for heart disease patients undergoing percutaneous coronary intervention (PCI).
The Society for Cardiovascular Angiography & Interventions (SCAI) has named George Dangas, MD, PhD, Professor of Medicine (Cardiology), and Surgery, at the Icahn School of Medicine at Mount Sinai as its new President.
For the 24th consecutive year, The Mount Sinai Hospital’s Cardiac Catheterization Laboratory or its interventionalists have received the highest two-star safety rating from the New York State Department of Health (NYSDOH) for percutaneous ...
Pulsed field ablation represents a potential paradigm shift in AF ablation. The modality is a more tissue-specific form of energy delivery than thermal, involving the application of high-intensity direct current pulses of short duration ...
A large-scale international study led by Mount Sinai has yielded the first risk score that can help predict mortality for patients with atrial fibrillation (AFib) who have undergone a successful transcatheter aortic valve replacement (TAVR) ...
Chronic, insufficient sleep can negatively affect immune cells, which may lead to inflammatory disorders and cardiovascular disease, according to a new study from the Icahn School of Medicine at Mount Sinai.
Use of anatomic testing such as coronary artery calcium scoring (CACS) of 0 to avoid myocardial perfusion imaging in symptomatic patients could lead to missing microvascular dysfunction in 4 out of 10 patients, a finding associated with a high mortality risk.
This large study of patients undergoing PET MPI demonstrated that although reduced MBFR was more prevalent in women compared with men, there were no sex-specific differences in the prognostic value of reduced MBFR.
Dr. Adams presents Dr. Anyanwu, who explores the options and tradeoffs in aortic valve replacement, and the issues that should be discussed between doctor and patient.
Join Ismail El-Hamamsy, MD, PhD, as he discusses the latest in aortic valve surgery in non-elderly adults, and reviews what is new in the literature on this topic
Ismail El-Hamamsy, MD, PhD, Professor of Cardiovascular Surgery, discusses The Ross Procedure, providing a step-by-step guide to optimize long-term durability and reviews what is new in the literature on this procedure.
A novel device called venous external support (VEST) may lead to increased longevity and durability of saphenous (leg) vein grafting during coronary artery bypass surgery, according to a new trial done in collaboration with Mount Sinai ...
Filip Swirski, PhD, an internationally recognized leader in cardiovascular immunology research, is the inaugural Director of the new Cardiovascular Research Institute.
Use of a novel technique called the quantitative flow ratio (QFR) to precisely identify and measure the severity of artery blockages can lead to significantly improved outcomes after percutaneous coronary intervention (PCI), according ...
A study showing the safety and effectiveness of a leadless cardiac pacemaker for right ventricular pacing has set the stage for research into a novel dual-chamber device that would serve a significantly broader population of patients with ...
An updated risk score can help predict possible contrast-associated acute kidney injury (CA-AKI) among patients undergoing percutaneous coronary intervention (PCI), according to Mount Sinai Heart researchers, led by Roxana Mehran, MD, ...
A scientific statement outlining unique considerations and suggestions for managing heart failure patients during the COVID-19 pandemic was issued in September 2021 by the Heart Failure Society of America, and Anuradha Lala, MD, Assistant ...
The Ross procedure may be a more favorable option for aortic valve replacement among patients under 50 years old than more standard mechanical or biological replacements, according to a study from Mount Sinai Heart.
A novel device called venous external support (VEST) may lead to increased longevity and durability of saphenous (leg) vein grafting during coronary artery bypass surgery, according to a multicenter trial coordinated by the Icahn School ...
Cardiometabolic syndrome (CMS) is diabetes mellitus (or insulin resistance) plus any two of the following risk factors: hypertension, obesity, and hyperlipidemia.
Post hoc analysis data demonstrated pegozafermin treatment significantly reduced triglycerides and other atherogenic lipids in patients with SHTG regardless of their background lipid-modifying therapy status.
Deepak Bhatt, MD, MPH, Director of Mount Sinai Heart, outlines the results for the HALO trial, explaining that a post hoc analysis revealed that a cluster of patients in one of the study arms was nonadherent; when results for adherent ...
Learn about the groundbreaking cardiovascular care offered at the Mount Sinai Health System. Ranked by U.S. News & World Report as No. 6 in the nation for Cardiology and Heart Surgery, Mount Sinai Heart at The Mount Sinai Hospital is recognized internationally as a leader in advancing all aspects of cardiology care, cardiac surgery, and cardiovascular research. Under the leadership of Valentín Fuster, MD, PhD, our team of award-winning physicians is expanding the field of knowledge in cardiovascular medicine, including treatments for arrhythmias, coronary artery disease, heart failure, valvular disease, and vascular disease.
